Advancing a class on top of statins
Gemphire's Mission
Our mission is to develop novel drugs, such as gemcabene, to treat the large, growing unmet need of dyslipidemia patients who are unable to reach optimal LDL cholesterol or triglyceride levels with statin or other therapies.
About Gemcabene

We are developing our product candidate gemcabene, a first-in-class, once-daily oral therapy, for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy. Gemcabene’s dual mechanism of action is designed to both inhibit the production of fatty acids and cholesterol in the liver and enhances the clearance of very low-density lipoproteins (VLDLs) in plasma. To learn more about gemcabene click here.